临床试验的未来在异常性肺纤维化症的临床试验
Paolo Spagnolo1, Toby M Maher2,3
1Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Current opinion in pulmonary medicine
|July 4, 2024
概括
对异形性肺纤维化 (IPF) 的晚期临床试验面临挑战. 改进试验设计,终点和招募策略是提高新IPF疗法的成功率的关键.
科学领域:
- 肺部医学 肺部医学
- 纤维化研究 纤维化研究
- 临床试验设计 临床试验设计
背景情况:
- 异形性肺纤维化 (IPF) 是一种进展性肺病,治疗选择有限,预后不佳.
- 在IPF中进行晚期临床试验存在重大设计和执行挑战.
- 几种有前途的候选药物未能在IPF第三阶段试验中证明有效性.
研究的目的:
- 审查异常性肺纤维化 (IPF) 晚期临床试验中的挑战.
- 讨论终点选择在试验成功中的关键作用.
- 探索创新的策略,以提高IPF临床试验的效率和成功.
主要方法:
- 对IPF最近的第三阶段临床试验结果的审查.
- 对终点选择的分析,包括患者报告的结果 (PRO).
- 在临床试验设计中评估外部控制臂的实用性.
主要成果:
- 在IPF第3期试验中,Ziritaxestat,pentraxin-2和pamrevlumab未能显示出有效性,尽管第2期的结果很有希望.
- 终点选择,专注于患者报告的结果 (患者如何感觉,功能和生存),对于将科学目标与患者需求相协调至关重要.
- 从历史数据中获得的外部控制臂,为减少研究持续时间,成本和增加概括性提供了潜在的好处.
结论:
- 研究设计,终点选择和统计分析方面的进步对于提高晚期IPF试验的成功至关重要.
- 参与者招募的创新策略可以提高试验效率.
- 要克服IPF临床研究中的挑战,需要采用多方面的方法,包括设计,终点和招聘.
更多相关视频
相关概念视频
COPD: Pathogenesis and Clinical Features
257
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
257
Pulmonary Function Tests
316
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
316
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K


